Search clinical trials for: Tislelizumab, pemetrexed

Total 1512 results

Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Eli Lilly and Company

Completed

Trial of Pemetrexed or Pemetrexed With Gemcitabine for Patients With Advanced Lung Cancer Who Are Not Eligible for Platinum-Based Chemotherapy and Have Not Previously Been Treated With Chemotherapy

Non-Small Cell Lung Cancer

Germany, Italy, United Kingdom
Eli Lilly and Company

Completed

A Phase II Study of a Combination of MTA (LY231514) and Gemcitabine in Patients With Metastatic Breast Cancer.

Breast Neoplasms

United States
The First Hospital of Jilin University
The Second Hospital of Hebei Medical University; Second Affiliated Hospital... and other collaborators

Active, not recruiting

Intrathecal Pemetrexed for Leptomeningeal Metastasis

Leptomeningeal Metastases

China
Pengyuan Liu

Recruiting

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (CRPC)

China
Sun Yat-sen University

Recruiting

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Non-small Cell Lung Cancer

China
Fujian Cancer Hospital

Not yet recruiting

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Immunotherapy
First Affiliated Hospital of Zhejiang University

Recruiting

Tislelizumab Combined With Chemotherapy as Neoadjuvant Therapy for Stage IIIA-IIIB (N2) Lung Squamous Cell Carcinoma (TACT)

Neoadjuvant Therapy | Immunotherapy | Lung Squamous Cell Carcinoma

China
German CLL Study Group

Active, not recruiting

Efficacy and Safety of Zanubrutinib Plus Tislelizumab for Treatment of Patients With Richter Transformation (CLL-RT1)

Richter Transformation

Denmark, Germany, Austria
Shanghai Kanda Biotechnology Co., Ltd.

Not yet recruiting

KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors

Other Solid Tumors | Advanced HCC

China
Wei Xu

Recruiting

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Chemotherapy Effect | Gene Mutation-Related Cancer | Tislelizumab | Cancer of Unknown Primary | Bone Cancer Metastatic | Immune Evasion, Tumor

China
Sun Yat-sen University

Recruiting

Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases

Brain Metastases | Non-Small Cell Squamous Lung Cancer

China
Tianjin Medical University Second Hospital

Active, not recruiting

Perioperative Tislelizumab Combined With Nab-Paclitaxel for Muscle-invasive Urothelial Bladder Carcinoma

Urothelial Carcinoma | Muscle Invasive Bladder Cancer

China
Fujian Cancer Hospital

Not yet recruiting

A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer

Mid-low Rectal Cancer
Henan Provincial People's Hospital

Not yet recruiting

Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse Astrocytoma

Astrocytoma of Brain

China
Tianjin Medical University Second Hospital

Recruiting

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable: a Multi-center Study

High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma

China
Tianjin Medical University Second Hospital

Recruiting

Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable

Non-Muscle Invasive Bladder Urothelial Carcinoma | High-Risk

China
BeiGene

Recruiting

Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma

China
Latin American Cooperative Oncology Group
Janssen, LP

Recruiting

Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations (AMIGO-1)

Metastatic Non-small Cell Lung Cancers

Brazil
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Terminated

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Head and Neck Cancer

United States
Eli Lilly and Company

Completed

Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Neoplasms

United States
BeiGene

Active, not recruiting

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Locally Advanced and Metastatic Solid Tumors

China, Taiwan, United States, Australia
Gustave Roussy, Cancer Campus, Grand Paris

Recruiting

Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority Study (Pulse)

Metastatic Non-squamous Lung Cancer

France
Institut für Klinische Krebsforschung IKF GmbH...
Bristol-Myers Squibb

Active, not recruiting

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Pleural Mesothelioma Malignant

Germany
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Pemetrexed, Carboplatin, and Bevacizumab as First-Line Therapy in Treating Older Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

United States
Duke University
Eli Lilly and Company

Terminated

Adjuvant Cisplatin With Either Genomic-Guided Vinorelbine or Pemetrexed for Early Stage Non-Small-Cell Lung Cancer (TOP0703)

Carcinoma, Non-Small-Cell Lung

United States
Columbia University

Terminated

A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Carcinoma (NSCLC)

Non-Small Cell Lung Cancer

United States
Veeda Oncology
Eli Lilly and Company; Sanofi; Genentech, Inc.

Completed

A Phase II Study of Eloxatin and Alimta in Combination With Bevacizumab in Advanced Non-Squamous NSCLC

Non-Small Cell Lung Cancer

United States
Fujian Medical University Union Hospital

Recruiting

Effect of Astragalus Membranaceus on the Improvement of Cognitive Function in Alzheimer's Disease

Alzheimer's Disease

China
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations

Non-Small Cell Lung Cancer With HER2- Mutations

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Fox Chase Cancer Center
Eli Lilly and Company

Terminated

Pemetrexed and Gemcitabine in Patients With Advanced Head and Neck Cancer

Head and Neck Cancer

United States
Tufts Medical Center
Eli Lilly and Company

Terminated

Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer

Carcinoma, Small Cell

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

LY231514 Plus Gemcitabine in Treating Women With Metastatic Breast Cancer

Breast Cancer

United States, Canada
Cancer Institute and Hospital, Chinese Academy...

Unknown

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

Adenocarcinoma | NSCLC | Squamous Cell Carcinoma
Jiangsu Healthy Life Innovation Medical Technology...

Not yet recruiting

TTField in Combination With TMZ and Tislelizumab in The Treatment of Newly Diagnosed Glioblastoma.

Glioblastoma Multiforme
Li Xiao Wei

Not yet recruiting

HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL) (HAI-TL)

Hepatocellular Carcinoma With PVTT

China
Fujian Cancer Hospital

Recruiting

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Immunotherapy Gastrict Cancer

China
Seoul National University Bundang Hospital
Novartis Korea Ltd.

Completed

Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head (EZAPCOFH)

Avascular Necrosis of Femoral Head

Korea, Republic of
Sun Yat-sen University
Chongqing University Cancer Hospital; Xiangya Hospital of Central South University and other collaborators

Recruiting

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma

China
Hebei Medical University Fourth Hospital

Recruiting

Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Ottawa Hospital Research Institute

Completed

Does Thinning the Blood During Surgery Prevent Blood Clots Following Total Knee Replacement Surgery

Osteoarthritis | DVT

Canada
Tang-Du Hospital

Unknown

Preventive Effects of Zoledronic Acid on Bone Metastasis in Patients With Stage IIIB and IV Lung Cancer

Lung Cancer

China
Boehringer Ingelheim

Recruiting

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Lung Cancer, Non-squamous, Non-small Cell

Australia, Korea, Republic of, China, Japan, United States, Hong Kong, Singapore, Taiwan
Peking Union Medical College

Recruiting

Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC

Non-small Cell Lung Cancer | EGFR T790M | Osimertinib | ddPCR

China
Kobe City General Hospital

Terminated

The Safety and Efficacy of Pemetrexed Rechallenge With Bevacizumab

Advanced Non-small Cell Lung Cancer

Japan
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer

Liver Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Shanghai Chest Hospital
Changhai Hospital; Ruijin Hospital

Unknown

Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial

Lung Adenocarcinoma
Sun Yat-sen University

Recruiting

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Pleural Mesothelioma

China
Nanfang Hospital of Southern Medical University
Jiangsu Hengrui Pharmaceutical Co., Ltd.

Recruiting

Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients (PANORAMA)

Chemotherapy | Immunotherapy

China

3

Subscribe